References
- Cacabelos R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov. 2018;13(6):523–538.
- Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177.
- Foroutan N, Hopkins RB, Tarride JE, et al. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: a systematic review and network meta-analysis. Clin Invest Med. 2019;42(1):53–65.
- Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408(6815):979–982.
- Herline K, Drummond E, Wisniewski T. Recent advancements toward therapeutic vaccines against Alzheimer’s disease. Expert Rev Vaccines. 2018;17(8):707–721.
- Novak P, Zilka N, Zilkova M, et al. AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis. 2019;6(1):63–69.
- Hoskin JL, Sabbagh MN, Al-Hasan Y, et al. Tau immunotherapies for Alzheimer’s disease. Expert Opin Investig Drugs. 2019;28(6):545–554.
- Carrera I, Fernandez-Novoa L, Aliev G, et al. Validating Immunotherapy in Alzheimer’s disease: the EB101 vaccine. Curr Pharm Des. 2016;22(7):849–858.
- Zhang HY, Zhu K, Meng Y, et al. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice. Brain Res Bull. 2018;142:233–240.
- Rosenberg RN, Fu M, Lambracht-Washington D. Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimers Res Ther. 2018;10(1):115.
- Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321–332.
- Frost JL, Liu B, Rahfeld JU, et al. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice. Neurobiol Aging. 2015;36(12):3187–3199.
- Cacabelos R, Carril JC, Sanmartín A, et al. Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics and nutriepigenenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Amsterdam: Elsevier/Academic Press; 2019. p. 191–424.
- Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–442.
- Panza F, Frisardi V, Imbimbo BP, et al. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy. 2010;2(6):767–782.
- Cribbs DH. Abeta DNA vaccination for Alzheimer’s disease: focus on disease prevention. CNS Neurol Disord Drug Targets. 2010;9(2):207–216.
- Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. [ cited 2018 Sep 17]:1733807. DOI:10.1016/j.neulet.2018.09.018.
- Rothman SM, Tanis KQ, Gandhi P, et al. Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology. J Neuroinflammation. 2018;15(1):256.
- Cacabelos R, editor. World guide for drug use and pharmacogenomics. Corunna (ES): EuroEspes Publishing; 2012.
- Zepp F. Principles of vaccination. Methods Mol Biol. 2016;1403:57–84.
- Bachmann MF, Jennings GT, Vogel M. A vaccine against Alzheimer`s disease: anything left but faith? Expert Opin Biol Ther. 2019;19(1):73–78.